009420.KS KSC
Hanall Biopharma Co., Ltd.
1W: -1.1%
1M: -16.3%
3M: -25.2%
YTD: -14.9%
1Y: +66.1%
3Y: +131.5%
5Y: +108.6%
₩46,100.00 ($34.34)
-2400.00 (-4.95%)
Weekly Expected Move ±7.7%
₩39018
₩42559
₩46100
₩49641
₩53182
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap₩2.34T ($1.7B)
52W Range32600-73000
Volume261,279
Avg Volume476,215
Beta0.88
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOSu-Jin Park
Employees315
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2000-01-04
Websitehanall.com/kr
43, Sangseodang 1-gil
Daejeon, DE 04386
KR
Daejeon, DE 04386
KR
+82 2 6440 7000
About Hanall Biopharma Co., Ltd.
HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceuticals. It offers products such as medicine for digestion, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives, and other pharmaceutical products. The company was founded by Byeong-Tae Kim on November 20, 1973 and is headquartered in Daejeon, South Korea.
Latest News
No recent news
Recent Insider Trades
No insider trades found